11    Sanofi    $11.8    down 3.3%
Global revenue: $43.8B (6th); up 3.3%

R&D spend: $6.7B (6th), up 11.7%; 15.3% of rev.

Top brands: Lantus ($2.3B); Eloxatin ($806M); Lovenox ($633M); Taxotere ($243M); Plavix ($196M)

Planned launches: Teriflunomide (MS), visamerin (VTE), Lemtrada (MS), lixisenatide (diab.)

Promotional spend: $477M (12th); 4.0% of rev.

Patent expirations: Plavix (2012), Multaq (2014), Actonel (2014)

The diabetes medication merchant said in February that it expects business to fall off between 12% and 15% this year, as it weathers the aftershocks of patent losses on Lovenox, Ambien CR, Taxotere and Plavix. But it hopes to add diabetes treatment lixisenatide, a GLP-1 agonist scheduled to be filed this year. The GLP-1 field is a crowded one; Sanofi could bump up against Amylin's newcomer, Bydureon. Despite the uncertainty, Sanford Bernstein analyst Tim Anderson praised the company, in part because its patent cliff levels off next year.

Back to first page